U.S. Markets close in 3 hrs 7 mins

Palatin Technologies, Inc. (PTN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.5506+0.0027 (+0.49%)
As of 12:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5479
Open0.5500
Bid0.5504 x 900
Ask0.5508 x 800
Day's Range0.5500 - 0.5508
52 Week Range0.3800 - 1.3000
Volume638,180
Avg. Volume1,827,062
Market Cap126.666M
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.1190
Earnings DateMay 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Palatin Announces Adjournment of Annual Meeting of Stockholders
    PR Newswire

    Palatin Announces Adjournment of Annual Meeting of Stockholders

    Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021, has been adjourned until July 8, 2021 at 9:00 a.m. Eastern Daylight Time to solicit additional proxies for Proposal 3, approval of an amendment to our Certificate of Incorporation to effect an increase in authorized common stock from 300,000,000 shares to 400,000,000 shares. The adjourned meeting will be a completely "virtual" meeting of stockholders,

  • ACCESSWIRE

    Palatin Technologies, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Palatin Technologies, Inc. (NYSE:PTN) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on May 17, 2021 at 11:00 AM Eastern Time.

  • Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update
    PR Newswire

    Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update

    Palatin (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced results for its third fiscal quarter ended March 31, 2021.